Novel Cleavable Nucleotides for DNA Sequencing by Synthesis

Information

  • Research Project
  • 7404752
  • ApplicationId
    7404752
  • Core Project Number
    R43HG004470
  • Full Project Number
    1R43HG004470-01A1
  • Serial Number
    4470
  • FOA Number
    PA-07-80
  • Sub Project Id
  • Project Start Date
    4/9/2008 - 16 years ago
  • Project End Date
    3/31/2010 - 14 years ago
  • Program Officer Name
    SCHLOSS, JEFFERY
  • Budget Start Date
    4/9/2008 - 16 years ago
  • Budget End Date
    3/31/2010 - 14 years ago
  • Fiscal Year
    2008
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    4/7/2008 - 16 years ago

Novel Cleavable Nucleotides for DNA Sequencing by Synthesis

[unreadable] DESCRIPTION (provided by applicant): Intelligent Bio-Systems is developing a high-speed, low-cost DNA sequencing-by-synthesis (SBS) system which is based on the use of cleavable fluorescent nucleotides with reversible terminator technology. The cleavable linkers utilized in these nucleotides enable efficient removal of fluorescent signals and the reversible terminator technology enables reliable sequencing of repeats. In order to extend the performance of the sequencing system, we believe it is important to minimize the effect of residual linker on the nucleotide bases left behind after cleavage. These residual linkers may disturb the DNA duplex structure and interfere with a polymerase's ability to incorporate subsequent nucleotides. The goal of this Phase I project is to synthesize and evaluate several novel cleavable nucleotides which generate minimal residues after cleavage. We anticipate that the use of such nucleotides should result in much higher cumulative cycle efficiency in the SBS and enable longer sequencing reads. [unreadable] [unreadable] During Phase I of this project we will synthesize, characterize and extensively evaluate two novel designs of nucleotides which will generate smaller residues after fluorescent signal removal. The performance of novel nucleotides will be compared with the performance of our standard design cleavable nucleotides in solution and on solid surfaces. During Phase II we will synthesize and characterize 4 nucleotides based on the best performing analogs and perform synthesis optimization and scale-up. Phase II will also involve evaluation of all 4 nucleotides in our sequencing instrument. Ultimately, the ability to produce very inexpensive detailed DNA sequence information for complex organisms' genomes will both lead to accelerated discoveries throughout biology and provide the basis for Pharmacogenomics, a new paradigm in therapeutics wherein medicines are prescribed based on individual genotypes rather than just observed symptoms. [unreadable] [unreadable] [unreadable]

IC Name
NATIONAL HUMAN GENOME RESEARCH INSTITUTE
  • Activity
    R43
  • Administering IC
    HG
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    162574
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    172
  • Ed Inst. Type
  • Funding ICs
    NHGRI:162574\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    INTELLIGENT BIO-SYSTEMS, INC.
  • Organization Department
  • Organization DUNS
    170777770
  • Organization City
    Waltham
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    02451
  • Organization District
    UNITED STATES